Scientists around the world are working together to help fight the disease that has already claimed the lives of millions since the dawn of humanity. Dr. Mikhail Blagosklonny and Andrei V. Gudkov have developed an open-access platform for oncologists to use, called Oncotarget, which was introduced in 2010. They are hoping that by inventing a platform that would allow the oncologists to upload their findings and sending it to the system, their colleagues from the other side of the planet who knows more can check it out and formulate something useful about it. Download output styles at Endnote.com Oncologists worldwide are racing against time, and they are doing their best to create a powerful tool that can be used against cancer. They have been using several methods today including chemotherapy to fight cancer, but these methods are leaving a disastrous side effect on the patient’s body. Dr. Mikhail Blagosklonny and Andrei V. Gudkov are hoping that a better cure can be developed, and with Oncotarget, they are hoping that oncologists are brainstorming and sharing ideas that could one day result to the formulation of the cure. Learn more about Oncotarget at Eurekalert.org.
Oncotarget posts new articles online twice every week, and everyone can access the information that they publish. Oncologists are grateful about the development of the platform because they would have a better method to upload their findings, and they are thankful by the fact that even the smallest findings can be uploaded for the whole scientific community to see. Dr. Mikhail Blagosklonny and Andrei V. Gudkov, the editors in chief of Oncotarget, have also decided to shift to podcast broadcasting. According to them, every article or journal published by Oncotarget will have an audio version, to enable full readings of each study. The authors of each publication will also be given a chance to have an interview with the hosts and explain further what the findings are all about. Dr. Mikhail Blagosklonny and Andrei V. Gudkov are excited for the debut of the platform, saying that it is another highlight to the growth of Oncotarget, and they are welcoming other methods or options on how to share the articles within Oncotarget to the world.
— Oncotarget (@OncotargetJrnl) December 5, 2017